Improving Outcome of Aplastic Anaemia with HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantation: An Experience of Gujarat Cancer and Research Institute (GCRI)

• Published in: Indian journal of hematology & blood transfusion Vol. 31; no. 1; pp. 1 - 8
• Main Authors: Raut, Shreeniwas S., Shah, Sandip A., Patel, Kinnari A., Shah, Kamlesh M., Anand, Asha S., Talati, Shailesh S., Panchal, Harsha P., Patel, Apurva A., Parikh, Sonia K., Parekh, Bhavesh B., Shukla, Shilin N.
• Format: Journal Article
• Language: English
• Published: India Springer India 01.03.2015; Springer Nature B.V
• Subjects: Anemia; Blood & organ donations; Blood Transfusion Medicine; Cancer; Clinical outcomes; Graft versus host disease; Hematology; Human Genetics; Medical research; Medicine; Medicine & Public Health; Oncology; Original; Original Article; Patients; Stem cell transplantation; Stem cells; Transplants & implants; Gujarat India; Aplastic anaemia; Gujarat; Allogeneic bone marrow transplantation; HLA-matched sibling-donor; Peripheral blood stem cell transplantation
• ISSN: 0971-4502; 0974-0449; 0974-0449; 0971-4502
• DOI: 10.1007/s12288-014-0397-x

Fifteen patients, with a median age of 19 years having severe aplastic anaemia (SAA) underwent human leucocyte antigen (HLA) identical sibling donor hematopoietic stem cell transplantation (HSCT) using conditioning regimens containing cyclophosphamide with antithymocyte globulin (ATG) or a combination of fludarabine and cyclophosphamide with or without ATG during December 2007 to May 2013. Cyclosporine and mini methotrexate were used as graft versus host disease (GVHD) prophylaxis. Graft source included peripheral blood stem cells in 11, bone marrow in 3 and both in 1. One patient had primary graft failure while 14 patients were engrafted with a median neutrophil and platelet engraftment time of 13.5 days. One patient had secondary graft rejection. Acute GVHD occurred in 3 patients and chronic GVHD in 4. One year death rate in engrafted patients was 14.28 %. At a mean follow-up of 21.2 months, 12 (80 %) are alive and well. One of the donors was a patient of haemophilia but the disease did not occur in the recipient. The graft was successful and the recipient is alive till date.